difluprednate (durezol) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Difluprednate is a corticosteroid used as an anti-inflammatory steroidal drug used primarily in ocular surgery. It is thought to act by the induction of phospholipase A2 inhibitory proteins (lipocortins). It is postulated that these proteins control the biosynthesis of potent mediators of infammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. It is marketed by Alcon under the tradename Durezol.   NCATS

Chemistry

  • SMILES: CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)COC(C)=O
  • InChIKey: WYQPLTPSGFELIB-JTQPXKBDSA-N
  • Mol. Mass: 508.5515
  • ALogP: 3.52
  • ChEMBL Molecule:
    difluprednate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: Yes

Drug Pricing (per unit)

United States

$26.9500 - $39.7951
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

6 alpha-9-difluoroprednisolone 21-acetate 17-butyrate | c.m.9155 | dfba | difluoroprednisolone butyrate acetate | difluprednate | durezol | epitopic | w-6309

Organizations (25)

Research & Development (20)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (12)

Approved Indications (2)


 

Inflammation

Uveitis, Anterior

Experimental Indications - Clinical Trial Phases 1-4 (12)


 

Cataract (Phase 4)

Corneal Edema (Phase 4)

Dry Eye Syndromes (Phase 2)

Inflammation (Phase 3)

Keratitis (Phase 4)

Macular Edema (Phase 4)

Pain (Phase 3)

Panuveitis (Phase 3)

Retinal Diseases (Phase 4)

Uveitis (Phase 4)

Uveitis, Anterior ()

Visual Pathways (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 22
  • # of Trial Organizations: 20

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue